EMA to support development of vaccines and treatments for novel coronavirus disease

On 04 February 2020 the EMA announced to support development of vaccines and treatments for novel coronavirus disease.

To contribute to the global response to the outbreak of the novel coronavirus (2019-nCoV) infections, EMA is taking concrete actions to accelerate the development and availability of medicinal products for the treatment and prevention of the new coronavirus.

The Agency is surveying the landscape for potential antivirals or vaccines to treat or prevent novel coronavirus infections. EMA is also analysing all available information on developers’ drug pipelines.

Developers working on medicinal products or vaccines that could be used for treatment or prevention of novel coronavirus 2019-nCoV infections are encouraged to contact the Agency and discuss their strategy for evidence generation as soon as possible. They can contact EMA by sending an email to This email address is being protected from spambots. You need JavaScript enabled to view it. for initial discussions with EU regulators.

Read more online
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /